<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213810</url>
  </required_header>
  <id_info>
    <org_study_id>SHCS 610</org_study_id>
    <nct_id>NCT01213810</nct_id>
  </id_info>
  <brief_title>Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive
      individuals. Study participants are stratified into different patient groups according to
      their CD4 cell count, viral load and HIV Status.

        -  Trial with medicinal product

        -  Trial with immunomodulatory product / biological
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>half a year</time_frame>
    <description>Geometric mean titer of Varicella zoster virus-specific IgG, VZV-specific T- cells per 106 peripheral mononuclear cells, Frequency of VZV-specific T- cells of total T-cells, CD4+ T-cells in different HIV-positive persons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>half a year</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability&quot;</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Herpes Zoster</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>Biological/Vaccine</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: All individuals

          -  Age &gt;18 years

          -  Male, or female with negative urine pregnancy test

          -  VZV-seropositive (serologically documented)

          -  Agree to use a barrier method of birth control (such as a condom)

          -  Written informed consent HIV positive individuals on ART (group A1-A3)

          -  Continuous ART for &gt;3 months before baseline

          -  No change of ART regimen within 1 month before baseline

          -  HIV-RNA (value must be &lt;3 months old )&lt;50 copies/ml at last visit

          -  CD4-count (value must be &lt;3 months old) &gt; 500 cells/µl for group A1, 350-500 cells/µl
             for group A2 and 250 -349 cells/µl for group A3

          -  Participation in the SHCS HIV-positive individuals without ART (group B)

          -  HIV-1 RNA &gt;1000 copies/ml (&lt;3 months before baseline)

          -  CD4-cell count &gt;500 cells/µl (&lt;3 months before baseline)

          -  Participation in the SHCS Healthy HIV-negative volunteers (group C)

          -  Negative HIV-screening test (&lt;3 months before baseline)

          -  CD4 cell count &gt;500 cells/µl

        Exclusion criteria: Common exclusion criteria

          -  Contraindications on ethical grounds

          -  Involvement in a conflicting (vaccine or investigational drug) clinical trial (except
             from the participation in the Swiss HIV Cohort Study).

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders or dementia of the subject.

          -  Pregnancy or breast feeding.

          -  Other clinically relevant concomitant disease states (e.g., renal failure, hepatic
             dysfunction, cardiovascular disease, etc),

          -  Known or suspected non-compliance, drug- or alcohol abuse.

        Specific exclusion criteria

          -  Fever &gt; 38.3 °C or acute illness during the last 4 weeks

          -  Exposure to chickenpox or shingles within four weeks prior to study entry

          -  History of shingles

          -  Immunosuppression due to disease (other than HIV) or due to medication within 30 days
             of study entry (eg corticosteroids)

          -  Household contact with known immunodeficiency (e.g. HIV-positive with CD4 &lt;250
             cells/µl)

          -  Immunoglobulin or blood product treatment within 1 year prior or 2 month after study
             vaccination

          -  Previous allergic reaction to vaccine components (i.e. neomycin or gelatin)

          -  Vaccination with a life attenuated vaccine one month prior to study entry

          -  History of chickenpox vaccination

          -  Treatment with anti-herpes drugs 4 weeks before baseline

          -  Severe coagulation disorder or oral anticoagulant treatment

          -  Laboratory exclusion criteria.

               -  Thrombocytopenia &lt; 50x 103/?l

               -  Haemoglobin &lt;12 g/dl

               -  More than threefold elevation of ALT

               -  Creatinine of more than150 µmol/l

               -  Glucose &gt;10 mmol/l
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Hasse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology</affiliation>
  </overall_official>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>VZV (Varicella zoster Virus)</keyword>
  <keyword>vaccine</keyword>
  <keyword>T cell</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

